Literature DB >> 17297476

SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas.

S J Moschos1, A P Smith, M Mandic, C Athanassiou, K Watson-Hurst, D M Jukic, H D Edington, J M Kirkwood, D Becker.   

Abstract

Although patients diagnosed with melanoma of </= 1.00 mm thickness have a relatively good cure rate, the prognosis for patients with locally advanced and metastatic melanoma is grave. The discovery of new and effective therapies for this disease depends in large part on molecular studies that will resolve why advanced-stage melanoma is refractory to conventional chemotherapy and radiation therapy. To identify genes that have important functions in advanced-stage melanomas, in particular, in melanoma-infiltrated lymph nodes, which are not well characterized at the molecular level, we generated a LongSAGE library from a melanoma-positive lymph node, and subjected melanoma-infiltrated lymph nodes to protein expression profiling. The data document that the molecular signature of melanoma, which has spread to regional lymph nodes, is very similar to the molecular signature of primary melanomas. Equally important, we provide evidence that the ubiquitin-conjugating enzyme, Ubc9, is expressed at high levels in melanoma-positive lymph nodes, and that it plays a crucial role in preventing advanced-stage melanomas from undergoing chemotherapy-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297476     DOI: 10.1038/sj.onc.1210216

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  S-adenosyl methionine regulates ubiquitin-conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers.

Authors:  Maria Lauda Tomasi; Ivan Tomasi; Komal Ramani; Rosa Maria Pascale; Jun Xu; Pasquale Giordano; José M Mato; Shelly C Lu
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

Review 2.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

3.  NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.

Authors:  M P Licciardello; M K Müllner; G Dürnberger; C Kerzendorfer; B Boidol; C Trefzer; S Sdelci; T Berg; T Penz; M Schuster; C Bock; R Kralovics; G Superti-Furga; J Colinge; S M Nijman; S Kubicek
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

4.  Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner.

Authors:  S Zhu; M Sachdeva; F Wu; Z Lu; Y-Y Mo
Journal:  Oncogene       Date:  2009-12-21       Impact factor: 9.867

5.  Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.

Authors:  Alexander Hoellein; Mohammad Fallahi; Stephanie Schoeffmann; Sabine Steidle; Franz X Schaub; Martina Rudelius; Iina Laitinen; Lisa Nilsson; Andrei Goga; Christian Peschel; Jonas A Nilsson; John L Cleveland; Ulrich Keller
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

Review 6.  SUMO and the robustness of cancer.

Authors:  Jacob-Sebastian Seeler; Anne Dejean
Journal:  Nat Rev Cancer       Date:  2017-01-30       Impact factor: 60.716

7.  Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.

Authors:  Christopher Abdullah; Xiaolei Wang; Dorothea Becker
Journal:  Cell Cycle       Date:  2011-03-15       Impact factor: 4.534

8.  SUMO, PTEN and Tumor Suppression.

Authors:  Michael J Matunis; Catherine M Guzzo
Journal:  Pigment Cell Melanoma Res       Date:  2012-07-31       Impact factor: 4.693

9.  Oncoproteomic profiling with antibody microarrays.

Authors:  Mohamed Ss Alhamdani; Christoph Schröder; Jörg D Hoheisel
Journal:  Genome Med       Date:  2009-07-06       Impact factor: 11.117

10.  MicroRNA-mediated regulation of Ubc9 expression in cancer cells.

Authors:  Fangting Wu; Shuomin Zhu; Yanna Ding; William T Beck; Yin-Yuan Mo
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.